Drugs / tamuzimod
tamuzimod
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04451811 | Sep 2020 → Feb 2021 | — | Oppilan Pharma Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07287397 | Dec 2025 → Oct 2027 expected | amyotrophic lateral sclerosis | Vector Y Therapeutics | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05156125 | Nov 2021 → Aug 2023 | ulcerative colitis | Oppilan Pharma Ltd | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tamuzimod | “Tamuzimod (VTX002) is a selective sphingosine 1-phosphate receptor 1 modulator in development for ulcerative colitis.” PMID 39793589 ↗ Jan 2025 |
| Known as | OPL-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04451811 ↗ |
| Known as | VTX002 | “Tamuzimod (VTX002) is a selective sphingosine 1-phosphate receptor 1 modulator in development for ulcerative colitis.” PMID 39793589 ↗ Jan 20252“intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS).” NCT07287397 ↗ |
| Modality | Small molecule | — CHEMBL5314488 ↗ |
| Route | Oral | “oral OPL-002” NCT04451811 ↗ |